IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8 +T cells

Journal of Immunology

Volumn 188, Issue 4, 2012, Pages 1609-1619

  Imataki, Osamu ^a,b,c   Ansén, Sascha ^a,b,c,g   Tanaka, Makito ^a,b,c   Butler, Marcus O ^a,b,c   Berezovskaya, Alla ^a   Milstein, Matthew I ^a   Kuzushima, Kiyotaka ^d   Nadler, Lee M ^a,b,c   Hirano, Naoto ^a,b,c,e,f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 21; MAJOR HISTOCOMPATIBILITY ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE LCK; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HUMANS; INTERLEUKINS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MAJOR HISTOCOMPATIBILITY COMPLEX; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84863156418     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003446     Document Type: Article

References (68)

1. Zamoyska, R. 1998. CD4 and CD8: modulators of T-cell receptor recognition of antigen and of immune responses? Curr. Opin. Immunol. 10: 82-87. (Pubitemid 28112084)
2. Luescher, I. F., E. Vivier, A. Layer, J. Mahiou, F. Godeau, B. Malissen, and P. Romero. 1995. CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. Nature 373: 353-356.
3. Wooldridge, L., H. A. van den Berg, M. Glick, E. Gostick, B. Laugel, S. L. Hutchinson, A. Milicic, J. M. Brenchley, D. C. Douek, D. A. Price, and A. K. Sewell. 2005. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J. Biol. Chem. 280: 27491-27501. (Pubitemid 41076859)
4. Purbhoo, M. A., J. M. Boulter, D. A. Price, A. L. Vuidepot, C. S. Hourigan, P. R. Dunbar, K. Olson, S. J. Dawson, R. E. Phillips, B. K. Jakobsen, et al. 2001. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J. Biol. Chem. 276: 32786-32792.
5. Veillette, A., M. A. Bookman, E. M. Horak, and J. B. Bolen. 1988. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell 55: 301-308.
6. Buslepp, J., S. E. Kerry, D. Loftus, J. A. Frelinger, E. Appella, and E. J. Collins. 2003. High affinity xenoreactive TCR:MHC interaction recruits CD8 in absence of binding to MHC. J. Immunol. 170: 373-383. (Pubitemid 36026162)
7. Holler, P. D., and D. M. Kranz. 2003. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18: 255-264. (Pubitemid 36263000)
8. Kerry, S. E., J. Buslepp, L. A. Cramer, R. Maile, L. L. Hensley, A. I. Nielsen, P. Kavathas, B. J. Vilen, E. J. Collins, and J. A. Frelinger. 2003. Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J. Immunol. 171: 4493-4503. (Pubitemid 37310564)
9. Laugel, B., D. A. Price, A. Milicic, and A. K. Sewell. 2007. CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions. Eur. J. Immunol. 37: 905-913. (Pubitemid 46925328)
10. Choi, E. M., J. L. Chen, L. Wooldridge, M. Salio, A. Lissina, N. Lissin, I. F. Hermans, J. D. Silk, F. Mirza, M. J. Palmowski, et al. 2003. High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J. Immunol. 171: 5116-5123. (Pubitemid 37432794)
11. Pittet, M. J., V. Rubio-Godoy, G. Bioley, P. Guillaume, P. Batard, D. Speiser, I. Luescher, J. C. Cerottini, P. Romero, and A. Zippelius. 2003. Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J. Immunol. 171: 1844-1849. (Pubitemid 36966467)
12. Price, D. A., J. M. Brenchley, L. E. Ruff, M. R. Betts, B. J. Hill, M. Roederer, R. A. Koup, S. A. Migueles, E. Gostick, L. Wooldridge, et al. 2005. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J. Exp. Med. 202: 1349-1361. (Pubitemid 41668738)
13. Andrews, N. P., C. D. Pack, and A. E. Lukacher. 2008. Generation of antiviral major histocompatibility complex class I-restricted T cells in the absence of CD8 coreceptors. J. Virol. 82: 4697-4705. (Pubitemid 351657032)
14. Casey Crooks, M. E., and D. R. Littman. 1994. Disruption of T lymphocyte positive and negative selection in mice lacking the CD8 beta chain. Immunity 1: 277-285.
15. Fung-Leung, W. P., T. M. Kündig, K. Ngo, J. Panakos, J. De Sousa-Hitzler, E. Wang, P. S. Ohashi, T. W. Mak, and C. Y. Lau. 1994. Reduced thymic maturation but normal effector function of CD8+ T cells in CD8 beta gene-targeted mice. J. Exp. Med. 180: 959-967. (Pubitemid 24256608)
16. Riddle, D. S., P. J. Miller, B. G. Vincent, T. B. Kepler, R. Maile, J. A. Frelinger, and E. J. Collins. 2008. Rescue of cytotoxic function in the CD8alpha knockout mouse by removal of MHC class II. Eur. J. Immunol. 38: 1511-1521.
17. Angelov, G. S., P. Guillaume, and I. F. Luescher. 2009. CD8beta knockout mice mount normal anti-viral CD8+ T cell responses: but why? Int. Immunol. 21: 123-135.
18. Nakayama, K., K. Nakayama, I. Negishi, K. Kuida, M. C. Louie, O. Kanagawa, H. Nakauchi, and D. Y. Loh. 1994. Requirement for CD8 beta chain in positive selection of CD8-lineage T cells. Science 263: 1131-1133. (Pubitemid 24105958)
19. de la Calle-Martin, O., M. Hernandez, J. Ordi, N. Casamitjana, J. I. Arostegui, I. Caragol, M. Ferrando, M. Labrador, J. L. Rodriguez-Sanchez, and T. Espanol. 2001. Familial CD8 deficiency due to a mutation in the CD8 alpha gene. J. Clin. Invest. 108: 117-123. (Pubitemid 32634928)
20. Ma, A., R. Koka, and P. Burkett. 2006. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol. 24: 657-679.
21. Spolski, R., and W. J. Leonard. 2008. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26: 57-79. (Pubitemid 351600371)
22. Rochman, Y., R. Spolski, and W. J. Leonard. 2009. New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 9: 480-490.
23. Wang, X., P. Lupardus, S. L. Laporte, and K. C. Garcia. 2009. Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27: 29-60.
24. Bezbradica, J. S., and R. Medzhitov. 2009. Integration of cytokine and heterologous receptor signaling pathways. Nat. Immunol. 10: 333-339.
25. Verdeil, G., J. Chaix, A. M. Schmitt-Verhulst, and N. Auphan-Anezin. 2006. Temporal cross-talk between TCR and STAT signals for CD8 T cell effector differentiation. Eur. J. Immunol. 36: 3090-3100. (Pubitemid 44932711)
26. McAdam, A. J., B. E. Gewurz, E. A. Farkash, and A. H. Sharpe. 2000. Either B7 costimulation or IL-2 can elicit generation of primary alloreactive CTL. J. Immunol. 165: 3088-3093.
27. Ansén, S., M. O. Butler, A. Berezovskaya, A. P. Murray, K. Stevenson, L. M. Nadler, and N. Hirano. 2008. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin. Cancer Res. 14: 6125-6136.
28. Butler, M. O., J. S. Lee, S. Ansén, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, and N. Hirano. 2007. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin. Cancer Res. 13: 1857-1867. (Pubitemid 46952956)
29. Li, Y., M. Bleakley, and C. Yee. 2005. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175:2261-2269. (Pubitemid 41113833)
30. Oh, S., L. P. Perera, D. S. Burke, T. A. Waldmann, and J. A. Berzofsky. 2004. IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc. Natl. Acad. Sci. USA 101: 15154-15159. (Pubitemid 39391734)
31. Hirano, N., M. O. Butler, Z. Xia, S. Ansén, M. S. von Bergwelt-Baildon, D. Neuberg, G. J. Freeman, and L. M. Nadler. 2006. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107: 1528-1536. (Pubitemid 43242391)
32. Butler, M. O., O. Imataki, Y. Yamashita, M. Tanaka, S. Ansén, A. Berezovskaya, G. Metzler, M. I. Milstein, M. M. Mooney, A. P. Murray, et al. Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PLoS ONE. In press.
33. Kuzushima, K., N. Hayashi, A. Kudoh, Y. Akatsuka, K. Tsujimura, Y. Morishima, and T. Tsurumi. 2003. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells. Blood 101: 1460-1468. (Pubitemid 36182521)
34. Perez, O. D., D. Mitchell, R. Campos, G. J. Gao, L. Li, and G. P. Nolan. 2005. Multiparameter analysis of intracellular phosphoepitopes in immunophenotyped cell populations by flow cytometry. Curr. Protoc. Cytom. Chapter 6: Unit 6.20.
35. Hirano, N., M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansén, S. Kojima, and L. M. Nadler. 2006. Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood 108: 2662-2668.
36. Hirano, N., M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansén, and L. M. Nadler. 2006. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin. Cancer Res. 12: 2967-2975. (Pubitemid 43837340)
37. Cheroutre, H. 2005. IELs: enforcing law and order in the court of the intestinal epithelium. Immunol. Rev. 206: 114-131. (Pubitemid 41105166)
38. Karaki, S., M. Tanabe, H. Nakauchi, and M. Takiguchi. 1992. Beta-chain broadens range of CD8 recognition for MHC class I molecule. J. Immunol. 149: 1613-1618.
39. Renard, V., P. Romero, E. Vivier, B. Malissen, and I. F. Luescher. 1996. CD8 beta increases CD8 coreceptor function and participation in TCR-ligand binding. J. Exp. Med. 184: 2439-2444. (Pubitemid 27023746)
40. Wheeler, C. J., P. von Hoegen, and J. R. Parnes. 1992. An immunological role for the CD8 beta-chain. Nature 357: 247-249.
41. Wooldridge, L., M. Clement, A. Lissina, E. S. Edwards, K. Ladell, J. Ekeruche, R. E. Hewitt, B. Laugel, E. Gostick, D. K. Cole, et al. 2010. MHC class I molecules with superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. J. Immunol. 184: 3357-3366.
42. Laugel, B., H. A. van den Berg, E. Gostick, D. K. Cole, L. Wooldridge, J. Boulter, A. Milicic, D. A. Price, and A. K. Sewell. 2007. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J. Biol. Chem. 282: 23799-23810. (Pubitemid 47328005)
43. Salio, M., D. Shepherd, P. R. Dunbar, M. Palmowski, K. Murphy, L. Wu, and V. Cerundolo. 2001. Mature dendritic cells prime functionally superior melan-Aspecific CD8+ lymphocytes as compared with nonprofessional APC. J. Immunol. 167: 1188-1197. (Pubitemid 32703112)
44. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Liénard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64: 2865-2873. (Pubitemid 38500627)
45. Valitutti, S., S. Müller, M. Dessing, and A. Lanzavecchia. 1996. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183: 1917-1921. (Pubitemid 26134333)
46. Kessler, B., D. Hudrisier, M. Schroeter, J. Tschopp, J. C. Cerottini, and I. F. Luescher. 1998. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production. J. Immunol. 161: 6939-6946. (Pubitemid 28562241)
47. Xu, X. N., M. A. Purbhoo, N. Chen, J. Mongkolsapaya, J. H. Cox, U. C. Meier, S. Tafuro, P. R. Dunbar, A. K. Sewell, C. S. Hourigan, et al. 2001. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity 14: 591-602. (Pubitemid 32520870)
48. Hemmer, B., I. Stefanova, M. Vergelli, R. N. Germain, and R. Martin. 1998. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J. Immunol. 160: 5807-5814. (Pubitemid 28298038)
49. Kawakami, Y., and S. A. Rosenberg. 1997. Human tumor antigens recognized by T-cells. Immunol. Res. 16: 313-339. (Pubitemid 28026418)
50. Pittet, M. J., A. Zippelius, D. Valmori, D. E. Speiser, J. C. Cerottini, and P. Romero. 2002. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol. 23: 325-328. (Pubitemid 34717898)
51. Romero, P., D. Valmori, M. J. Pittet, A. Zippelius, D. Rimoldi, F. Lévy, V. Dutoit, M. Ayyoub, V. Rubio-Godoy, O. Michielin, et al. 2002. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188: 81-96. (Pubitemid 35398867)
52. Alanio, C., F. Lemaitre, H. K. Law, M. Hasan, and M. L. Albert. 2010. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood 115: 3718-3725.
53. Blattman, J. N., R. Antia, D. J. Sourdive, X. Wang, S. M. Kaech, K. Murali-Krishna, J. D. Altman, and R. Ahmed. 2002. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J. Exp. Med. 195: 657-664. (Pubitemid 34461511)
54. Wooldridge, L., S. L. Hutchinson, E. M. Choi, A. Lissina, E. Jones, F. Mirza, P. R. Dunbar, D. A. Price, V. Cerundolo, and A. K. Sewell. 2003. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J. Immunol. 171: 6650-6660. (Pubitemid 37532097)
55. Wooldridge, L., T. J. Scriba, A. Milicic, B. Laugel, E. Gostick, D. A. Price, R. E. Phillips, and A. K. Sewell. 2006. Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. Eur. J. Immunol. 36: 1847-1855. (Pubitemid 44089051)
56. Yee, C., P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162: 2227-2234. (Pubitemid 29288845)
57. Hodge, J. W., M. Chakraborty, C. Kudo-Saito, C. T. Garnett, and J. Schlom. 2005. Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 174: 5994-6004. (Pubitemid 40663786)
58. Oh, S., J. W. Hodge, J. D. Ahlers, D. S. Burke, J. Schlom, and J. A. Berzofsky. 2003. Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. 170: 2523-2530. (Pubitemid 36245642)
59. Xu, S., G. K. Koski, M. Faries, I. Bedrosian, R. Mick, M. Maeurer, M. A. Cheever, P. A. Cohen, and B. J. Czerniecki. 2003. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J. Immunol. 171: 2251-2261. (Pubitemid 37025530)
60. Cawthon, A. G., H. Lu, and M. A. Alexander-Miller. 2001. Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8alphabeta versus CD8alphaalpha expression. J. Immunol. 167: 2577-2584. (Pubitemid 32768885)
61. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102-4107. (Pubitemid 26144250)
62. Walter, S., L. Herrgen, O. Schoor, G. Jung, D. Wernet, H. J. Bühring, H. G. Rammensee, and S. Stevanović. 2003. Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. J. Immunol. 171: 4974-4978. (Pubitemid 37432775)
63. Li, J., W. Shen, K. Kong, and Z. Liu. 2006. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand. J. Immunol. 64: 515-522. (Pubitemid 44536336)
64. Skak, K., M. Kragh, D. Hausman, M. J. Smyth, and P. V. Sivakumar. 2008. Interleukin 21: combination strategies for cancer therapy. Nat. Rev. Drug Discov. 7: 231-240.
65. Elsaesser, H., K. Sauer, and D. G. Brooks. 2009. IL-21 is required to control chronic viral infection. Science 324: 1569-1572.
66. Fröhlich, A., J. Kisielow, I. Schmitz, S. Freigang, A. T. Shamshiev, J. Weber, B. J. Marsland, A. Oxenius, and M. Kopf. 2009. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324: 1576-1580.
67. Yi, J. S., M. Du, and A. J. Zajac. 2009. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324: 1572-1576.
68. Butler, M. O., P. Friedlander, M. I. Milstein, M. M. Mooney, G. Metzler, A. P. Murray, M. Tanaka, A. Berezovskaya, O. Imataki, L. Drury, et al. 2011. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci. Transl. Med. 3: 80ra34.